Latest news with #ZacksMedical-BiomedicalandGenetics
Yahoo
2 days ago
- Business
- Yahoo
Are You Looking for a Top Momentum Pick? Why Exelixis (EXEL) is a Great Choice
Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades. Even though momentum is a popular stock characteristic, it can be tough to define. Debate surrounding which are the best and worst metrics to focus on is lengthy, but the Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us. Below, we take a look at Exelixis (EXEL), which currently has a Momentum Style Score of A. We also discuss some of the main drivers of the Momentum Style Score, like price change and earnings estimate revisions. It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Exelixis currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market over the following one-month period. You can see the current list of Zacks #1 Rank Stocks here >>> Let's discuss some of the components of the Momentum Style Score for EXEL that show why this drug developer shows promise as a solid momentum pick. A good momentum benchmark for a stock is to look at its short-term price activity, as this can reflect both current interest and if buyers or sellers currently have the upper hand. It's also helpful to compare a security to its industry; this can show investors the best companies in a particular area. For EXEL, shares are up 1.53% over the past week while the Zacks Medical - Biomedical and Genetics industry is up 0.25% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 16.08% compares favorably with the industry's 3.88% performance as well. While any stock can see a spike in price, it takes a real winner to consistently outperform the market. Over the past quarter, shares of Exelixis have risen 15.14%, and are up 91.03% in the last year. In comparison, the S&P 500 has only moved 1.99% and 12.34%, respectively. Investors should also pay attention to EXEL's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. EXEL is currently averaging 3,763,384 shares for the last 20 days. The Zacks Momentum Style Score encompasses many things, including estimate revisions and a stock's price movement. Investors should note that earnings estimates are also significant to the Zacks Rank, and a nice path here can be promising. We have recently been noticing this with EXEL. Over the past two months, 10 earnings estimates moved higher compared to none lower for the full year. These revisions helped boost EXEL's consensus estimate, increasing from $2.31 to $2.61 in the past 60 days. Looking at the next fiscal year, 9 estimates have moved upwards while there have been 1 downward revision in the same time period. Given these factors, it shouldn't be surprising that EXEL is a #2 (Buy) stock and boasts a Momentum Score of A. If you're looking for a fresh pick that's set to soar in the near-term, make sure to keep Exelixis on your short list. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Exelixis, Inc. (EXEL) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
17-05-2025
- Business
- Yahoo
Are You Looking for a Top Momentum Pick? Why DBV Technologies S.A. (DBVT) is a Great Choice
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades. Even though momentum is a popular stock characteristic, it can be tough to define. Debate surrounding which are the best and worst metrics to focus on is lengthy, but the Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us. Below, we take a look at DBV Technologies S.A. (DBVT), which currently has a Momentum Style Score of A. We also discuss some of the main drivers of the Momentum Style Score, like price change and earnings estimate revisions. It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. DBV Technologies S.A. Currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market over the following one-month period. You can see the current list of Zacks #1 Rank Stocks here >>> In order to see if DBVT is a promising momentum pick, let's examine some Momentum Style elements to see if this company holds up. A good momentum benchmark for a stock is to look at its short-term price activity, as this can reflect both current interest and if buyers or sellers currently have the upper hand. It's also helpful to compare a security to its industry; this can show investors the best companies in a particular area. For DBVT, shares are up 9.83% over the past week while the Zacks Medical - Biomedical and Genetics industry is down 6.67% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 41.1% compares favorably with the industry's 0.95% performance as well. Considering longer term price metrics, like performance over the last three months or year, can be advantageous as well. Over the past quarter, shares of DBV Technologies S.A. Have risen 164.32%, and are up 90.53% in the last year. On the other hand, the S&P 500 has only moved -2.89% and 12.85%, respectively. Investors should also pay attention to DBVT's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. DBVT is currently averaging 100,932 shares for the last 20 days. The Zacks Momentum Style Score encompasses many things, including estimate revisions and a stock's price movement. Investors should note that earnings estimates are also significant to the Zacks Rank, and a nice path here can be promising. We have recently been noticing this with DBVT. Over the past two months, 1 earnings estimate moved higher compared to none lower for the full year. These revisions helped boost DBVT's consensus estimate, increasing from -$5.45 to -$1.15 in the past 60 days. Looking at the next fiscal year, 1 estimate has moved upwards while there have been no downward revisions in the same time period. Taking into account all of these elements, it should come as no surprise that DBVT is a #2 (Buy) stock with a Momentum Score of A. If you've been searching for a fresh pick that's set to rise in the near-term, make sure to keep DBV Technologies S.A. On your short list. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DBV Technologies S.A. (DBVT) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14-05-2025
- Business
- Yahoo
Codexis (CDXS) Reports Q1 Loss, Misses Revenue Estimates
Codexis (CDXS) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.16 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -25%. A quarter ago, it was expected that this producer of custom industrial enzymes would post a loss of $0.02 per share when it actually produced a loss of $0.13, delivering a surprise of -550%. Over the last four quarters, the company has not been able to surpass consensus EPS estimates. Codexis , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $7.54 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 28.99%. This compares to year-ago revenues of $17.07 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Codexis shares have lost about 46.3% since the beginning of the year versus the S&P 500's gain of 0.1%. While Codexis has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Codexis: favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.15 on $14.68 million in revenues for the coming quarter and -$0.62 on $65.74 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 30% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Roivant Sciences Ltd. (ROIV), another stock in the same industry, has yet to report results for the quarter ended March 2025. This company is expected to post quarterly loss of $0.16 per share in its upcoming report, which represents a year-over-year change of +30.4%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Roivant Sciences Ltd.'s revenues are expected to be $67.33 million, up 132.7% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Codexis, Inc. (CDXS) : Free Stock Analysis Report Roivant Sciences Ltd. (ROIV) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
13-05-2025
- Business
- Yahoo
Humacyte, Inc. (HUMA) Reports Q1 Loss, Lags Revenue Estimates
Humacyte, Inc. (HUMA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.29 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 47.37%. A quarter ago, it was expected that this company would post a loss of $0.23 per share when it actually produced a loss of $0.16, delivering a surprise of 30.43%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Humacyte, Inc. , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.52 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 2.45%. This compares to zero revenues a year ago. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Humacyte, Inc. Shares have lost about 73.9% since the beginning of the year versus the S&P 500's decline of -0.6%. While Humacyte, Inc. Has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Humacyte, Inc. Favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.14 on $1.05 million in revenues for the coming quarter and -$0.69 on $9.66 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 35% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, Opus Genetics, Inc. (IRD), has yet to report results for the quarter ended March 2025. This company is expected to post quarterly loss of $0.34 per share in its upcoming report, which represents a year-over-year change of -17.2%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Opus Genetics, Inc.'s revenues are expected to be $2.8 million, up 63.7% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Humacyte, Inc. (HUMA) : Free Stock Analysis Report Opus Genetics, Inc. (IRD) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
